StockNews.com Lowers DexCom (NASDAQ:DXCM) to Hold

StockNews.com cut shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a report published on Saturday.

A number of other research firms have also issued reports on DXCM. Morgan Stanley decreased their price objective on DexCom from $120.00 to $75.00 and set an equal weight rating on the stock in a research note on Friday, July 26th. JPMorgan Chase & Co. cut DexCom from an overweight rating to a neutral rating and decreased their price target for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Canaccord Genuity Group reissued a buy rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Piper Sandler restated an overweight rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Finally, Oppenheimer decreased their price objective on shares of DexCom from $150.00 to $115.00 and set an outperform rating on the stock in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $110.69.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $67.10 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The stock has a fifty day simple moving average of $69.94 and a two-hundred day simple moving average of $101.37. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market cap of $26.68 billion, a price-to-earnings ratio of 43.29, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company earned $0.34 EPS. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. Analysts anticipate that DexCom will post 1.69 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock valued at $126,390 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several institutional investors have recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the 2nd quarter worth about $25,000. Sachetta LLC grew its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC purchased a new position in shares of DexCom during the first quarter valued at approximately $29,000. Riverview Trust Co bought a new position in DexCom during the first quarter valued at approximately $32,000. Finally, DT Investment Partners LLC boosted its holdings in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.